Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Game-Changing Blood Test for Stroke Detection Could Bring Life-Saving Care to Patients

By LabMedica International staff writers
Posted on 20 May 2024

Stroke is the primary cause of disability globally and ranks as the second leading cause of death. More...

However, timely early intervention can prevent severe outcomes. Most strokes are ischemic, resulting from a blockage that disrupts blood flow to the brain. Large vessel occlusion (LVO) strokes, a severe form of ischemic stroke, occur when a major artery in the brain is obstructed. The brain cells begin to die within minutes due to the deprivation of oxygen and nutrients. LVO strokes are critical emergencies that necessitate rapid treatment with mechanical thrombectomy, a procedure that removes the obstruction. Now, a new test combines blood-based biomarkers with a clinical score to accurately identify patients suffering from LVO strokes.

Mechanical thrombectomy has revolutionized stroke treatment, potentially restoring individuals to full health as though they never experienced a stroke. The sooner this procedure is applied, the better the outcomes for patients. This groundbreaking technology, developed by researchers at Brigham and Women’s Hospital (Boston MA, USA), could significantly shorten the time to treatment worldwide. The study focused on two proteins in capillary blood: glial fibrillary acidic protein (GFAP), linked to brain bleeds and traumatic brain injury, and D-dimer. It was demonstrated that these biomarkers, in conjunction with the field assessment stroke triage for emergency destination (FAST-ED) scores, effectively identify LVO ischemic strokes and differentiate them from conditions like brain bleeds, which can present similar symptoms but require different treatments.

The researchers conducted a prospective, observational diagnostic accuracy study with a cohort of 323 stroke-coded patients from May 2021 to August 2022. They discovered that combining GFAP and D-dimer levels with FAST-ED scores within six hours from symptom onset allowed the test to detect LVO strokes with 93% specificity and 81% sensitivity. The test also successfully excluded all patients with brain bleeds, indicating potential future applications for detecting intracerebral hemorrhage in the field. This diagnostic tool shows promise for use in low- and middle-income countries, where advanced imaging might not be available, and for assessing traumatic brain injuries. Further research includes a new prospective trial to evaluate the test's effectiveness in ambulances, alongside an interventional trial designed to accelerate stroke patient triage by bypassing conventional imaging for direct intervention.

“We have developed a game-changing, accessible tool that could help ensure that more people suffering from stroke are in the right place at the right time to receive critical, life-restoring care,” said senior author Joshua Bernstock, MD, PhD, MPH, a clinical fellow in the Department of Neurosurgery at Brigham and Women’s Hospital.

Related Links:
Brigham and Women’s Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Portable POCT Blood Gas Analyzer
BD100
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.